MIT and Microsoft researchers created an AI model to design peptide-based sensors for ultra-early cancer detection by detecting cancer-specific enzymes.
Key Details
- 1The AI model, CleaveNet, rapidly designs peptides that are efficiently and specifically cleaved by cancer-linked proteases.
- 2Nanoparticles coated with these peptides serve as in vivo sensors, releasing detectable signals in urine if target proteases are present.
- 3This approach allows non-invasive at-home cancer screening, potentially detecting and distinguishing between up to 30 cancer types.
- 4The AI-enabled sensors demonstrated high specificity for proteases such as MMP13, linked to cancer metastasis.
- 5The research appears in Nature Communications (DOI: 10.1038/s41467-025-67226-1) and is supported by ARPA-H and several foundations.
Why It Matters
AI-guided molecular sensing represents a major step towards ultra-early, highly specific cancer detection, expanding the toolkit for noninvasive diagnostics. This molecular AI approach may complement or ultimately integrate with radiology and imaging AI, enhancing multidisciplinary cancer care and research in biomarkers.
Source
EurekAlert
Related News
•EurekAlert
NYU AI Model Improves 5-Year Breast Cancer Risk Prediction via 3D Mammograms
NYU researchers developed an AI model using longitudinal 3D mammograms that outperforms single-scan and 2D-based tools in predicting 5-year breast cancer risk.
•EurekAlert
Explainable AI Predicts High-Risk Heart Attack Patients for Imaging and Treatment
Researchers developed an explainable AI scoring system to predict intramyocardial hemorrhage risk after severe heart attacks, potentially guiding imaging decisions.
•EurekAlert
AI Framework Accelerates Aortic Aneurysm Risk Prediction from Imaging
Researchers developed BioPINN-LM, combining physics-informed neural networks and multimodal large language models to deliver fast, interpretable risk assessments for ascending thoracic aortic aneurysms.